Dowsett M, Detre S, Ormerod M G, Ellis P A, Mainwaring P N, Titley J C, Smith I E
Academic Department of Biochemistry, Royal Marsden Hospital, London, United Kingdom.
Cytometry. 1998 Aug 1;32(4):291-300.
Numerous recent studies have indicated the central role of apoptosis as a determinant of the growth abnormalities occurring with malignancy and of the effectiveness of a wide range of therapeutic manoeuvres in cancer treatment. However, there has been a relative paucity of studies measuring apoptosis in human solid tumours, because of the low incidence of apoptotic cells, the difficulty of identifying cells undergoing apoptosis, and the ethical and practical restrictions on obtaining repeat biopsies from patients during therapy. Fine-needle aspirates (FNAs) may be obtained from breast carcinomas as a minimally invasive technique allowing repeat sampling. We describe an approach in which the in situ end labelling (TUNEL) assay is applied to cells in FNAs prior to their analysis by flow cytometry, which allows many thousands of cells to be analysed automatically by objective criteria. Cells that were discriminated as apoptotic on flow cytometric analysis were sorted onto microscope slides and found to show nuclear morphology typical of apoptotic cells. A statistically significant relationship was found between the flow cytometric analysis and the conventional application of TUNEL on histological sections (P = 0.03). Repeat analyses of FNAs from 12 carcinomas showed a median 2.05% apoptotic cells and an overall coefficient of variation of 34.9%. Of the total variability in 12 tumours, 80% was attributed to variation between tumours, 12% between batches, and 8% was random. Thus, this technique should be able to detect the major differences in the percentage of apoptotic cells that occur between different tumours (range 0.3-11.3% by flow cytometry) and between different phases of treatment, and should provide a useful tool for further research on this process in solid tumours.
最近大量研究表明,细胞凋亡在恶性肿瘤发生时的生长异常以及癌症治疗中多种治疗手段的有效性方面起着核心作用。然而,由于凋亡细胞的发生率较低、识别正在经历凋亡的细胞存在困难以及在治疗期间从患者获取重复活检存在伦理和实际限制,测量人类实体瘤中细胞凋亡的研究相对较少。细针穿刺抽吸物(FNA)可作为一种微创技术从乳腺癌中获取,允许重复采样。我们描述了一种方法,即在通过流式细胞术分析之前,将原位末端标记(TUNEL)检测应用于FNA中的细胞,这使得数以千计的细胞能够根据客观标准自动分析。在流式细胞术分析中被判定为凋亡的细胞被分选到载玻片上,发现呈现出典型的凋亡细胞核形态。流式细胞术分析与TUNEL在组织切片上的常规应用之间存在统计学上的显著关系(P = 0.03)。对12例癌的FNA进行重复分析显示,凋亡细胞的中位数为2.05%,总体变异系数为34.9%。在12个肿瘤的总变异性中,80%归因于肿瘤之间的变异,12%归因于批次之间的变异,8%是随机变异。因此,这项技术应该能够检测出不同肿瘤之间(流式细胞术检测范围为0.3 - 11.3%)以及不同治疗阶段之间凋亡细胞百分比的主要差异,并且应该为实体瘤中这一过程的进一步研究提供一个有用的工具。